Patients with obstructive coronary artery disease (CAD) undergoing stent implantation have more ischemic events through 5 years post-implantation when implanted with the Absorb bioresorbable vascular scaffold (BVS) versus the XIENCE everolimus-eluting stent (EES), a meta-analysis of the ABSORB study shows.